On November 4, 2016, after the last multi-center clinical study protocol seminar in Shanghai, the second seminar was held in Shenzhen. Authoritative experts from all over the country were invited: Shen Kunling, Dean of Beijing Children's Hospital affiliated to Capital Medical University, and Lin Likai, Director of the Editorial Department of Standardization of Traditional Chinese Medicine.Professor Bo Zheng, First Hospital of Peking University, Professor of History of Peking University School of Pharmacy, Director of Zheng Yuejie, Shenzhen Children's Hospital, Professor Xiantao Zeng, Central South Hospital of Wuhan University, Zhang Chuan, West China Second Hospital, Peirong Wu Peirong, Shanghai Children's Hospital, Chen Chunsong, West China Second Hospital,Yin Qingfeng, General Manager, Jiangsu Famisheng Medical Technology Co., Ltd. A detailed discussion and refinement of the multi-center clinical protocol was conducted at the meeting, and the present experts spoke freely and fully affirmed the future of sultamicillin.

The meeting was chaired by President Shen Kunling and Director Lin, and the theme of the meeting and sultamicillin were introduced in detail.

Then, Chairman Wu Guangmei of Shenzhen Beimei Pharmaceutical Co., Ltd. made clear instructions on the orientation of the company, and set a grand vision for the future development direction and objectives of the company.

Next, the scheme was introduced in detail by Prof. Chen Zun of Jiangsu Famisen Medical Technology Co., Ltd.

Next, President Shen Kunling summarized the plan, raised questions and guidance, and discussed the implementation plan and feasibility of the plan with the experts present.

The meeting came to an end with a lively discussion among the experts, who had a very systematic and comprehensive discussion on the main programme content of the meeting, which will soon be formally implemented in major hospitals throughout the country.At the same time, the implementation of the program has strengthened Wu Guangmei's determination to adhere to the company's development of children's medicines.